Introduction
Tissue engineering utilises design and construction principles to manufacture replacement tissues exhibiting competent biological function (Tabata, 2003) . Regeneration or repair of critical-sized bone defects by substitution of damaged or diseased tissues requires an ability to recapitulate developmental biology processes and control tissue morphogenesis. Manipulation of tissue development and morphogenesis can be achieved through delivery of inductive signals replicating native in vivo microenvironmental cues. Utilisation of select growth factors enables controlled cell differentiation towards specified lineages (Sundelacruz and Kaplan, 2009 ). Spatiotemporal orchestration of growth factors in vivo is critical to successful bone tissue engineering strategies (Reddi, 2000) . The aim of this review was to assess the inductive signalling aspect of current bone tissue engineering strategies, and identify individual growth factors or combinations thereof which have shown in vivo success within animal models and have been scaled to large animals prior to clinical translation within humans. It is pertinent to understand current progress to evaluate optimum strategies that can be taken forward for further study.
There is currently a range of tissue-engineered solutions advocated for bone repair and yet there remains a need for demonstrable preclinical and clinical efficacy of materials with a proven capacity to repair bone damage resulting from disease, trauma or surgical intervention. It is estimated that 3.6 % of the UK population (of over 64 million) will suffer a bone fracture in their lifetime (Donaldson et al., 2008) . The risk of fracture increases with age and statistics show 1 in 3 women and 1 in 5 men over 50 years of age will experience an osteoporotic fracture; a growing concern in an increasingly aged population (van Staa et al., 2001) . The worldwide incidence of hip fracture is expected to increase 240 % and 310 % in women and men, respectively, Leslie, 2012; Gullberg et al., 1997) , resulting potentially in a rise from 1.6 million cases per annum to between 4.5 and 6.3 million cases (Cooper et al., 1992b) . Osteoporosis is a major cause of hip fractures with equally significant financial tolls derived from both immediate medical treatment and post-treatment aid for reduced mobility, disability and increased dependency (Keene et al., 1993; Leslie et al., 2012) . There are currently over 2 million osteoporosis sufferers in the UK alone whose medical treatment of related fractures (Borgstrom et al., 2010a; Borgstrom et al., 2010b; Strom et al., 2013 ) is predicted to cost over £2 billion by 2020 (Burge et al., 2001) . Throughout the rest of Europe, osteoporosis related fractures are estimated to cost £51 billion by 2050 (Kanis and Johnell, 2005) . In addition, typically 10 % of fractures fail to repair resulting in non-union and increased socio-economic costs. There are two categories of non-union, hypertrophic (callus formation but without union) and atrophic (no callus formation). Many factors contribute to non-union fractures including avascular necrosis, bone apposition failure, poor or loss of fixation, infection, and soft tissue imposition within the defect site. A study in 2007 showed that humeral, tibial and femoral non-unions cost £15.5K, £16.3K and £17.2K, respectively, on a 'best-case scenario' . Non-union may also occur following spinal fusion surgery (posterolateral lumbar arthrodesis). Over 200,000 spinal fusion procedures are performed per annum in the US, yet non-union occurs in 10-40 % of patients undergoing single-level fusions (Boden, 2000) . This is more frequent in patients undergoing multiple-level fusions. Increasing costs are expected in the future, as only a third of vertebral fractures come to clinical attention and are officially diagnosed (Cooper et al., 1992a) ; it is estimated that up to 29 % of vertebral fractures may go unrecognised in Europe alone (Delmas et al., 2005) . Improved diagnosis of bone-related cancers is also expected to see rising costs for treatment. More than 2,000 cases are diagnosed per annum in the UK and more than 3,000 in the US.
TISSUE ENGINEERED BONE USING SELECT GROWTH FACTORS: A COMPREHENSIVE REVIEW OF ANIMAL STUDIES AND CLINICAL TRANSLATION STUDIES IN MAN
It is thus important to understand the principles of the bone-healing cascade and manipulation with biomaterials and growth factors to aid development of successful tissue engineering strategies for effective bone regeneration and repair (Berner et al., 2012) . This review examines data published between 1965 and 2013. All bone tissue engineering studies detailing an in vivo response of selected growth factors, including bone morphogenetic protein 2 (BMP-2), BMP-7/osteogenic protein 1 (OP-1), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), parathyroid hormone (PTH), parathyroid hormone-related protein (PTHrP), transforming growth factor beta 3 (TGF-β3), vascular endothelial growth factor (VEGF) and Wnt proteins, or combinations thereof, utilising animal models or human trials were included. All studies were compiled from PubMed-NCBI using search terms including 'growth factor name', 'in vivo', 'model/ animal', 'human', and 'bone tissue engineering'. Focus is drawn to the in vivo success of osteoinductive growth factors both in animals and in humans.
Animal Model Selection
To understand and recapitulate the healing cascade, suitable bone defects must be established in vivo through the use of appropriate animal models. Animal models allow for standardisation or elimination of variables which contribute to the success or failure of tissue engineered materials; animals may be obtained from the same source or breed, and maintained under identical environmental conditions (Khan and Lane, 2004) . The bone defects must not exhibit spontaneous healing during the lifetime of the animal (Horner et al., 2010) . These critical-sized bone defects are dependent on multiple factors and remain difficult to define across anatomical location and species . Previous work has defined a critical-sized defect as "a segmental bone deficiency of a length that exceeds 2 to 2.5 times the diameter of the affected bone" (Gugala et al., 2007) . However, this definition is not often applied to defects within animal models, and the important parameters to report are defect size and location. Efficacy of any tissue-engineered constructs within these criticalsized defects is dependent on a number of variables detailed in Table 1 (Lindsey et al., 2006; Reichert et al., 2009; Rimondini et al., 2005) . Furthermore, when choosing a Table 1 . Factors affecting both study animal selection and efficacy of implanted constructs within these animal models.
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suitable species for study, additional factors also require further consideration as detailed in Table 1 (Pearce et al., 2007; Reichert et al., 2009) . A review of the literature by O' Loughlin et al. (2008) demonstrated clear preferences towards particular species for fracture related studies, including rat (38 %), rabbit (19 %), mouse (15 %), sheep (11 %), dog (9 %) and goat (4 %). The remaining 4 % comprised a wide selection of less frequently investigated animal models. Currently, no single animal model provides a representative comparison for human bone repair; rather each animal model is selected to address a particular research question. Advantages and disadvantages of current large and small animal models as human comparisons for bone tissue research are shown in Table 2 . Furthermore, it is apparent that, dependent on the research question, bones of the selected animal model should exhibit significant physiological and pathophysiological analogies to human bone, regarding both macro-and micro-structure (Table  3) . If animal studies are to inform clinical translation then models should be carefully selected to best recapitulate the in vivo bone environment within humans. Table 3 details the structure of bone, highlighting parameters that require consideration prior to animal model selection (Egermann et al., 2005; Liebschner, 2004) . Some aspects of animal bone structure may be similar to that of humans; however, a balance should be struck with those that are different from humans. For example, preliminary investigations of bone biology and response to growth factor combinations could be assessed within small animals such as mouse or rat, as they provide a high-throughput in vivo model with similar biochemical composition to humans, and existing literature would help evaluate and interpret data. Systems could then be transferred to large animal models to assess candidate growth factors or combinations thereof in a functional setting analogous to humans. For example, defect regeneration strategies could be assessed within sheep long bone fractures as a model for large bone defects in humans, where the scale, mechanical loading and bone composition are similar to humans.
Growth Factor Delivery Vehicles
Following selection of an animal model and formation of a suitable critical-sized defect, a scaffold material exhibiting multifactorial properties is typically required to fill or bridge the defect site (Butler et al., 2000) . Orthopaedic materials currently employed in bone regeneration studies comprise organic bone substitutes, synthetic biomaterials and/or inorganic materials (Table 4) . The suitability of a selected biomaterial scaffold is governed by four factors; i) biomimicry, ii) biocompatibility, iii) biodegradability and iv) biomechanics. Successful scaffolds are thought to be those that replicate host tissue 3D architecture (porosity and microstructure enabling cell migration and vascularisation) (Bonfield, 2006; Laschke et al., 2008; Ma, 2008) , and do not elicit an immunological or inflammatory response locally or systemically during either long or short-term integration. If degradation is required the material should degrade over time without production of toxic by-products, and endure mechanical and physiological stresses (Ghosh and Ingber, 2007; Howard et al., 2008; McMahon et al., 2008; Semino, 2008) . Hip replacement implants are often not biodegradable, rather these implant scaffolds are selected to exhibit corrosion resistance, durability and strength sufficient enough to last the lifetime of the patient (Schauss et al., 2006) . Biomechanical properties of interest include elasticity, thermostability and tensile strength of the constituent materials (El Haj et al., 2005; Guan and Davies, 2004; Lendlein and Langer, 2002) . Many researchers believe that bone scaffold material should ideally replicate/incorporate the extracellular matrix (ECM) and thus influence cell attachment, migration, proliferation, differentiation and resultant bone tissue organisation (Green et al., 2002; Karageorgiou and Kaplan, 2005; Shin et al., 2003; Yang et al., 2003) . A variety of materials have been designed to address this challenge exhibiting either a bioactive osteoconductive surface (Takimoto et al., 2003) , enhanced functionality as a consequence of cell-scaffold surface topography interactions (Cohen et al., 1993; Engel et al., 2008) , functionalisation with a bioactive coating, or impregnation with bioactive molecules (Murphy and Mooney, 1999; Zhang et al., 2009a) . Growth and development of functional engineered tissue is dependent on environmental cues, both physical and chemical (Burdick and VunjakNovakovic, 2009; Chan and Mooney, 2008; Quaglia, 2008) . Implanted scaffolds can be designed as a delivery system for essential growth factors critical to cellular proliferation and osteogenic differentiation (Basmanav et al., 2008; Cartmell, 2009; Kanczler et al., 2008) . Sustained release of encapsulated growth factors from implanted material scaffolds provides adequate localised osteoinduction at the defect site and has shown some success in vivo with respect to tissue engineered bone (Table 5) (Tabata, 2003) .
Alternative vehicles have also been utilised to deliver selected growth factors in vivo. Rather than direct delivery, the gene(s) encoding the selected growth factor(s) can be introduced to the defect site by means of viral transduction or non-viral transfection. As seen in mouse studies administering BMP-2 as the choice growth factor, either viral (Gazit et al., 1999) or plasmid vectors (Osawa et al., 2009) can be directly delivered to the defect site (Dupont et al., 2012) , or pre-treated cells can be delivered (Kallai et al., 2010) .
Individual Growth Factors
Growth factor choice in a tissue engineering approach is critical for successful bone formation. Notable growth factors known to be important for bone regeneration include BMP-2, BMP-7/OP-1, FGF, PDGF, PTH, PTHrP, TGF-β3, VEGF and Wnt proteins. These growth factors have been applied individually and in combination, through direct and indirect delivery vehicles (Table 5) . In vivo paracrine and autocrine signalling cascades leading to bone formation are complex and rely on strict spatiotemporal interplay between select growth factors. Teasing apart the individual roles that each growth factor plays within bone development and healing systems is of the highest Kimmel and Jee, 1982; Neyt et al., 1998; Pearce et al., 2007; Skurla and James, 2005) Newman et al., 1995; Pearce et al., 2007; Ravaglioli et al., 1996) (Aerssens et al., 1998; Gomes and Fernandes, 2010; Liebschner, 2004; O'Loughlin et al., 2008) Table 4 . Organic, inorganic and synthetic materials for orthopaedic applications in vivo.
BMP-2
The discovery of auto-induced bone formation in rabbits implanted with autologous demineralised, lyophilised bone segments by Marshall R. Urist in 1965 (Urist, 1965 led to the identification of osteoinductive signalling molecules named by Urist as 'bone morphogenetic proteins' (BMPs) (Urist and Strates, 1971 
erythropoietin), FGF (fibroblast growth factor), FTIR (fourier transform infrared spectroscopy), HA (hydroxyapatite), HAA-PVAH (hyaluronic acid and poly-vinyl alcohol functionalised with hydrazide groups), ID2 (1α-hydroxyvitamin D2), ID3 (1α-hydroxyvitamin D3), MMP (matrix metalloproteinase), MRI (magnetic resonance imaging), MSC (mesenchymal stem cell), OP-1 (osteogenic protein-1), ORX (orchiectomised), OVX (ovariectomised), PCL (poly caprolactone), PDLLA (poly-D, L-lactic acid), PEEK (polyetheretherketone), PEG (poly ethylene glycol), PET (positron emission tomography), PGA (poly glycolic acid), PLA (poly lactic acid), PLG (poly D,L-lactide-co-glycolide), PLGA (poly lactic co-glycolic acid), PLL (poly-L-lysine), PLLA (poly-L-lactide), pNIPAm-co-AAc (poly-(N-isopropylacrylamide-co-acrylic acid)), PPF (poly-propylene fumarate), pQCT (peripheral quantitative CT), PTFBA (perfluorotributylamine), PTFE (polytetrafluoroethylene), PTH (parathyroid hormone), PTHrP (parathyroid hormone receptor-related protein), PUR (polyurethane), PVA (poly-vinyl alcohol), PX (p arathyroidectomized), rhBMP-2 (recombinant human bone morphogenetic protein-2), RT-PCR (real time polymerase chain reaction), SEM (scanning electron microscopy), Sox9 (SRY (sex determining region Y)-box 9), TCP (tricalcium phosphate), TEM (transmission electron microscopy), TGFβ (transforming growth factor β), VEGF (vascular endothelial growth factor), VitD3 (vitamin D3), Wnt (wingless-type MMTV integration site family), and XTM (X-ray tomographic microscopy)
. # -number of publications. to BMP-8a) have a known osteochondral function (Even et al., 2012) . BMP-2 specifically, is a disulphide-linked homodimer with a known role in osteoblast differentiation. Abundant use of recombinant human BMP-2 (rhBMP-2) within animal models has demonstrated successful in vivo bone regeneration and repair, and has been extensively examined as an osteoinductive growth factor for tissue engineering (Supplementary Table 1) .
Direct administration of BMP-2
A review of the literature revealed variable increased bone formation and defect regeneration ranging between 1.2 and 21 fold in large animal models (He et al., 2009; , and 1.1 and 50 fold in small animal models (Ishihara et al., 2008; Tolli et al., 2011) (Table 5 ). To date, despite the wealth of reported studies there remains a lack of consensus concerning the optimum rhBMP-2 dose for effective bone defect repair. Applications of rhBMP-2 have utilised dosages between 5 μg and 100 mg in large animal studies (Gu et al., 2011; Nilsson et al., 1986) , and 0.1 μg and 5 mg in small animal models (Hayashi et al., 2009; Whang et al., 1998) . A few small animal studies have also used higher dosages up to 150 mg (Dohzono et al., 2009; Hou et al., 2012) . One explanation for the observed variable success and diverse dosages is the number of different size models and defects investigated. Large animal models included dog (Hussein et al., 2012) , goat , horse (Tsuzuki et al., 2012) , monkey (Bai et al., 2009 ), pig (Abbah et al., 2011 and sheep (Gu et al., 2011) . Small animal models included mouse (Yu et al., 2010b) , rabbit and rat . Bone defects investigated included both endochondral and intramembranous bone segmental defects (Boerckel et al., 2012; Kirker-Head et al., 1998; , lumbar fusions (Akamaru et al., 2003; Fu et al., 2009 ) and drill defects (He et al., 2009; Levi et al., 2010) , in addition to ectopic implants intramuscularly (Luca et al., 2010b; Saito et al., 2003) and subcutaneously (Fu et al., 2010; Kimura et al., 2010) . Consequently, it may be more informative for authors to reference concentration and volume within given defect dimensions rather than a simple dosage as a standard between models. This would aid comparison between studies and animals enabling direct assessment of dosage and defect regeneration correlation. However, employed rhBMP-2 concentrations vary considerably, from 1.6 μg/mL to 1.5 mg/mL for large animals (Itoh et al., 1998; Sheehan et al., 2003) , and 2 μg/ mL to 4 mg/mL for small animals (Bax et al., 1999; Woo et al., 2001 ). There does not appear to be any correlation between dosages and fold increase in bone formation or time to healing. Therefore, reporting both defect volume and implant volume would help comparison of studies.
It is important to clarify distinctions between studies and that ideal comparisons would be made between identical animals and anatomic defect locations, of which to date there are not enough publications for statistical comparison.
Indirect administration of BMP-2
Further studies have utilised indirect delivery by viral transduction or non-viral transfection of rhBMP-2 to
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the bone defect site with a view to enabling sustained localised growth factor delivery. The two main avenues for application are either virus particles/plasmid vectors (Dupont et al., 2012; Ishihara et al., 2008) , or transduced/ transfected cells (Lazard et al., 2011; Lin et al., 2008) . The former influences non-specific host cell-originated tissue regeneration, whilst the latter enables exogenous cell-derived tissue repair. Indirect delivery studies showed a maximum 9-fold increase in bone formation , demonstrating reduced tissue repair in comparison to direct delivery. This may be due to under-dosing at the defect site, resulting from inadequate uptake by endogenous cells or production by exogenous cells. Continuous production of rhBMP-2 at the defect site may also have had negative or limiting effects on bone formation, compared to a single dose in most direct delivery studies. Spatiotemporal delivery at the defect site is therefore of paramount importance for augmentation of defect regeneration.
Combination administration of BMP-2
The bone-healing cascade is a complex process whose effective recapitulation is dependent on an exquisite interplay between multiple growth factors ( Grimes et al., 2011) . A number of in vivo studies have thus investigated the use of growth factors in combination rather than single factor application (Table 5) . Wang et al. (2012) delivered 5 μg of BMP-2 and 5 μg of BMP-7 via an implanted collagen sponge within a minipig calvarial defect, and demonstrated a 1.5 fold increase in bone formation compared to either growth factor alone. Koh et al. (2008) also investigated BMP-2 and BMP-7 indirect delivery via implantation of transduced cells within a mouse calvarial defect. The study showed a maximum 2-fold increase in bone formation compared to individual growth factor administration. Combination with other factors also demonstrated increased bone formation; Fujimura et al. (2002) showed a maximum 3.3-fold increase with BMP-7 and FGF-2 treatment, compared to 1.7 fold with BMP-7 alone. Clearly, there are benefits to dual combinations over single factors. Other factors and compounds used in combination with rhBMP-2, whether directly or indirectly, included BMP binding protein (BBP) (Lee et al., 2011) , erythropoietin (Sun et al., 2012a) , FGF (Springer et al., 2008) , α4-integrin (Kumar et al., 2010a), Runx2 , TGF-β2 (Thorey et al., 2011) , tobramycin (Glatt et al., 2009 ) and zoledronic acid (Doi et al., 2011; Schindeler et al., 2011) . A number of studies have incorporated mesenchymal stem cells (MSCs) (Hou et al., 2007; Kim et al., 2009 ) providing a healthy inducible cell source within the defect site (Dawson et al., 2014) . Taken together these studies demonstrated between 1.1 and 4 fold (Hou et al., 2007; Thorey et al., 2011) increased bone formation and defect regeneration (Supplementary Table 1) . Interestingly, some studies have shown that combined growth factor delivery does not enhance bone formation in comparison to single growth factor application. Terella et al. (2010) and Springer et al. (2008) (Xiao et al., 2011; Zhang et al., 2011a) increase in bone formation. Co-administration with VEGF induced vessel ingrowth bringing endogenous cells to the defect site, which could be triggered by BMP-2 to differentiate towards the osteogenic lineage and deposit new bone matrix. Ultimately, the aim of combination treatment is to support and augment native healing processes, and to do so requires a specific spatiotemporal approach with select growth factors.
BMP-7/OP-1 BMP-7, also known as OP-1, constitutes another BMP family member routinely used in bone tissue engineering strategies (Supplementary Table 2 ). Many in vivo studies have utilised BMP-7 on the basis that its osteoinductive potential can drive enhanced bone defect regeneration (Kidder et al., 2009; Lee et al., 2013) .
Direct administration of BMP-7
Analogous to BMP-2, BMP-7 has been employed in many large (baboon (Ripamonti et al., 2001a) , dog (Fukuroku et al., 2007) , goat (den Boer et al., 2002) , monkey (Cook et al., 2002) and sheep (Cipitria et al., 2013) ) and small (minipig (Warnke et al., 2006) , mouse , rabbit (Haidar et al., 2010b) Success variability may be dosage dependent since direct administration of BMP-7 has ranged from 100 µg to 3.5 mg (Reichert et al., 2012; Ripamonti et al., 2000) in large animals (some studies employed 65 mg to 750 mg (Lind et al., 2001; Salkeld et al., 2001) ) and 0.025 µg to 3.5 mg (Sampath et al., 1992; Warnke et al., 2006) in small animals. However, it remains to be ascertained whether this suggested correlation is positive (higher dose results in higher bone formation Haidar et al., 2010b; Ripamonti et al., 2000) ), negative (higher dose results in lower bone formation (Cook et al., 2005; Soballe et al., 2004) ) or whether it indeed exists (bone formation remains unaffected by dosage (Hamdy et al., 2003; Leknes et al., 2008) ). Standardisation of a species-dependent bone defect model of specific dimensions and anatomic location, rather than a simply stated 'critical sized' defect, would inevitably aid interpretation of in vivo data. In turn, this would also help comparison between studies regarding the efficacy of individual growth factors such as BMP-7 to drive osteogenic bone formation. The variety of defects
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currently investigated include segmental (Chen et al., 2002; Forriol et al., 2009; Reichert et al., 2012) , drill Zhang et al., 2004) , fusion (Blattert et al., 2002; Grauer et al., 2004; Magin and Delling, 2001 ) and ectopic implantation intramuscularly (Haidar et al., 2010a; Spiro et al., 2010) and subcutaneously (Sampath et al., 1992; Wei et al., 2007) , which together emphasise the lack of and need for standardisation. Indeed, Takigami et al. (2007) showed that anatomic location of the defect affected the efficacy of implanted BMP-7 on bone regeneration, where treatment of 10 mm femoral defects at the proximal and distal ends demonstrated 1.5-fold increased and 1.4-fold decreased bone formation. Other interesting observations which warrant further investigation include non-augmentation of bone formation following BMP-7 treatment and altered structure of new bone. Mont et al. (2001) showed that bone formation was the same with or without BMP-7 administration on allograft. It is important therefore to choose the scaffold material carefully as endogenous factors within the graft matrix may have masked the effects of BMP-7. Lammens et al. (2009) also reported a lack of bone augmentation following BMP-7 administration on bone filler. Spiro et al. (2010) showed that diclofenac treatment altered BMP-7-induced bone structure, decreasing trabeculae number and increasing spacing. Encouragingly, alternative ways of controlling inflammation at the defect site include the addition of BBP, which demonstrated a 1.5-fold reduction (Lee et al., 2011) .
Indirect administration of BMP-7
An alternative delivery method for growth factor delivery, as previously discussed, is viral transduction or non-viral transfection. BMP-7 has been indirectly delivered through the use of viral particles (2 x 10 10 in large animals , and 1.8 to 2.5 x 10 11 in small animals (Dunn et al., 2005; Zhang et al., 2012b) ) and transduced/transfected cells (1 x 10 5 to 5 x 10 7 in large animals (Chaofeng et al., 2013; Zhu et al., 2010) , and 1 x 10 5 to 2 x 10 6 in small animals Zhang et al., 2010c) ). Zhang et al. (2007) demonstrated a 2-fold increase in bone formation after implantation of viral particles, whilst Zhu et al. (2010) demonstrated a 2.5-fold increase after implantation of transduced bone marrow stromal cells (BMSCs) into dog and goat, respectively. Interestingly, the same study by Zhu et al. showed that implantation of non-transduced BMSCs also increased bone formation, but to a lesser degree (1.5 fold). Clearly, addition of cells alone without modification or growth factor loading can enhance bone defect regeneration. Typically, small animal studies demonstrated a 1.03 to 5 fold Zhang et al., 2012b) increase in bone formation, although one study by Hidaka et al. (2003) reported 21 fold increased bone formation. However, this study investigated spinal fusion compared to segmental defects from lower fold increase studies.
Combination administration of BMP-7
Additional factors have been successfully utilised in combination with BMP-7 to aid bone regeneration. Combination of BMP-7 with BMP-2 constitutes an additive approach where two osteogenic factors are hypothesised to further enhance the osteogenic outcome, whilst keeping individual dosages low (Koh et al., 2008; Wang et al., 2012) . Alternatively, combinations with VEGF or TGF-β3 (Ripamonti et al., 2010) constitute mutualistic approaches where the angiogenic factor induces vessel ingrowth into the defect (2 fold (Zhang et al., 2010a) ), the chondrogenic factor induces cartilaginous matrix production to fill the defect void, and the osteogenic factor induces resultant callus mineralisation and eventual bone formation (three lineages important for recapitulation of the in vivo bone healing cascade). Other factors and compounds used in combination with BMP-7 include BBP (Lee et al., 2011) , FGF-2 , insulin-like growth factor 1 (IGF-1) , pamidronate (Yu et al., 2010a) , PDGF (Zhang et al., 2012a) , PTH (1-34) (Morgan et al., 2008) , TGF-β1 (Ripamonti et al., 2001b) and thrombospondin 1 (TSP-1) (Gelse et al., 2011) . Taken together these combinations have demonstrated increased defect regeneration from 1.4 to 5.3 fold in large animals (Ripamonti et al., 2010; Zhang et al., 2009b) , and 1.2 to 15 fold in small animals Zhang et al., 2012a) . Although enhanced bone formation was observed in most studies, fold increases were not superior to those investigating BMP-7 alone. This may be due to under or over-dosing of one or both of the delivered factors. Consequently, balance between combination choice and dosage should be carefully considered as one study demonstrated a 2-fold decrease in bone formation following high dose pamidronate (2 mg) compared to low dose (20 µg) pamidronate (Yu et al., 2010a) . A number of studies have also investigated BMP-7 combinations with cells including BMSCs (Zhang et al., 2011b) , MSCs (Tsiridis et al., 2007a) or osteoblasts (Reichert et al., 2011) . Rather than flood the defect site with copious exogenous growth factors, these approaches endeavoured to augment the effect of BMP-7 through addition of an inducible cell source, and demonstrated a 1.5-to 8.8-fold increase in bone formation (Reichert et al., 2011; Takigami et al., 2007) . Again, fold increases were not superior to those of BMP-7 alone, which may be due to non-optimal balance between dosage and cell number, or even non-optimal spatiotemporal delivery of BMP-7.
It is important to note that the different outcomes observed within all the collated studies described here, with the administration of BMP-2 and BMP-7 in vivo, may not solely be dependent on dosage but also on receptor expression. Inter-species receptor expression can vary considerably and may ultimately govern the response to BMP dosage.
FGF
FGFs constitute a large growth factor family with over 20 members and are involved in many biological processes from embryonic development regulating cell proliferation, migration and differentiation, to homeostasis orchestrating tissue maintenance and repair (Ornitz and Itoh, 2001 ). FGF-1 to FGF-10 all bind FGF receptors (FGFR) and have characterised functions in bone development and healing (Ornitz and Marie, 2002) . A review of the literature revealed the most abundant member utilised within bone tissue engineering strategies in vivo was FGF-2, also D Gothard et al.
Tissue engineered bone and clinical translation known as basic FGF (Hirata et al., 2013; Hong et al., 2010; Maehara et al., 2009; Shirakata et al., 2010) .
Direct administration of FGF
FGF-2 has been administered to large animal models, including dog Table 3 ). Considering related fold increases in bone formation within large (1.3 to 3 fold Shirakata et al., 2010) ) and small animals (1.1 to 16.4 fold (Goodman et al., 2003; Hong et al., 2010) ), it is interesting to note that higher dosages correlated with greater fold increases (defects with highest fold increase included tibial fracture and calvarial defect respective to large and small animals). Evidently, data suggest positive correlation between FGF-2 treatment and bone formation, potentially due to induced vessel ingrowth and ossification at the defect site (Guo et al., 2006; Maehara et al., 2009 (Bland et al., 1995; Dunstan et al., 1999; Kelpke et al., 2004) , and one study utilised FGF-18 (Carli et al., 2012) which has been shown to promote chondrogenesis amongst many other functions. FGF-1 was administered between 3 and 7 µg in small animal models, including mouse (Dunstan et al., 1999) , rabbit (Bland et al., 1995) and rat (Kelpke et al., 2004) . Dunstan et al. (1999) demonstrated 8 to 10 fold increased bone formation. However, the animal model was ovariectomised to create a state of osteoporosis and therefore resultant data require careful interpretation prior to comparison with that of other animal models. Fold increase would be expected to drop in a normal animal model as baseline bone regeneration levels would be higher than those in osteoporotic models. The same study also investigated injection of FGF-1 adjacent to mouse calvaria, which demonstrated a 3-fold increase in bone thickness. However, injection with FGF-2 exhibited a 7-fold increase in bone thickness, suggesting FGF-2 is a more potent osteoinductor compared to FGF-1. Kelpke et al. (2004) demonstrated increased osteogenesis assessed by alkaline phosphatase, osteocalcin and osteopontin expression; however, bone tissue formation was not reported. Increased blood vessel ingrowth was observed and reported to range between 2 and 2.6 fold. Augmentation of vasculature can be beneficial for bone regeneration as it supplies an endogenous inducible cell source to populate and repair the defect site. Carli et al. (2012) delivered 0.5 µg FGF-18 to a 5 mm segmental femoral defect and demonstrated a 5-fold increase in percentage bone volume. On first observation, this would suggest that FGF-18 is a potent osteoinductor; however, this is only one study and was tested within a mutated mouse model which showed impaired bone formation. Further study is required to draw conclusions regarding in vivo bone tissue formation efficacy of FGF-1 and FGF-18. (Tan et al., 2009) ) and small animals (mouse (Meng et al., 2012) , rabbit (Guo et al., 2006) and rat (Qu et al., 2011) ) through implantation of transfected cells (6.25 x 10 4 and 5 x 10 6 cells (Guo et al., 2006; Meng et al., 2012) ). Bone formation was modestly increased 2 to 2.7 fold (Kwan et al., 2011; Meng et al., 2012) . However, one study by Hall et al. (2007) reported a 53.5 fold increase in percentage cancellous bone area (0.4 % in the control group increased to 21.4 % in the FGF-2 treated group). As previously discussed, care should be taken when comparing this with other data as the animal model used was haematopoietic deficient resulting in decreased baseline healing and therefore elevated fold increases in comparison to normal animal models. Most direct administration studies deliver FGF-2 in a single dose direct to the defect site and may be encapsulated within a carrier for controlled release over time, whereas indirect administration through endogenous or exogenous cell expression leads to continuous FGF-2 delivery. Lower bone tissue augmentation observed within indirect administration studies may be a consequence of constant exposure to FGF-2 stimulation. A spatiotemporal release profile would be more suitable to bone tissueengineering strategies eligible for clinical translation.
Indirect administration of FGF FGF-2 has been indirectly delivered to both large (dog

Combination administration of FGF
Investigation of other tissues would aid understanding of whether lower fold increase in bone tissue was due to preference or induction of pre-bone tissue formation, such as osteoid deposition or cartilage production. Indeed, Iwaniec et al. (2003) demonstrated 8 fold increased osteoid deposition compared to 1.8 fold increased bone formation rate. Combinations should be carefully selected, as Behr et al. (2012) demonstrated that combination of FGF-2 with either BMP-2 or VEGF resulted in less bone formation compared to BMP-2 and VEGF in combination. However, growth factor selection should be made according to the task at hand, whereby combination treatment with FGF-2 may be required to induce void filling callus formation and osteoid production prior to combination treatment with BMP-2 for mineralisation. A staged approach may be necessary for efficient and effective bone healing requiring multiple growth factors delivered spatiotemporally in varying dosages. Following combination administration
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of FGF-2 with BMP-2 (van der Stok et al., 2013) , BMP-7 , oestrogen (Iwaniec et al., 2003) Park et al. (2000) demonstrated up to 10 fold increased bone formation; however, this was compared to healing within blank control defects. The same study demonstrated only a 1.5 fold increase in comparison to control defects filled with scaffold alone. Evidently, dependent on the controls used and comparisons made within individual studies, care should be taken when drawing conclusions regarding growth factor efficacy for bone regeneration in vivo. Careful consideration should also be afforded to which parameters are used to quantify growth factor efficacy, as Moore et al. (2009) reported 9 fold increased union but only 1.9 to 2.4 fold increased bone volume. Standardisation of comparable readouts across related growth factor investigations would ultimately provide fast and efficient cross-evaluation. PDGF appears to enhance bone regeneration through angiogenic induction and augmentation of surrounding vasculature. However, where increased bone formation is reported following high dose PDGF by Nash et al. (1994) reduced mechanical strength within newly formed bone was also reported. Quality alongside quantity of newly formed bone should therefore be factored into any analysis of bone defect regeneration. Although many studies have reported a positive correlation between PDGF administration and enhanced bone healing, these observations were not shared by all. Kaipel et al. (2012) demonstrated the failure of PDGF treatment to increase bone healing within a femoral segmental defect in rat. The same study also demonstrated failed healing following administration of another angiogenic factor VEGF. Interestingly, administration of BMP-2 within this study enhanced bone healing, suggesting that osteogenic factors are either a prerequisite for bone augmentation, or that they are required to drive progression of endogenous endochondral ossification. Anusaksathien et al. (2004) reported similar negative findings with continuous PDGF exposure where treatment resulted in reduced mineralisation at the defect site. Delivery was indirect, through implantation of transduced cells. However, reduction was observed after 3 weeks then reversed and increased after 6 weeks. This suggests that temporal exposure within a larger network of bone healing processes dictates the effect of implanted PDGF.
Indirect administration of PDGF
Addition of an angiogenic factor may not necessarily correlate with an angiogenic response, and is dependent on spatiotemporal delivery. Indeed, indirect administration of PDGF has been shown to modestly increase bone volume within the defect site between 1.7 and 2 fold (Zhang et al., 2012a) following delivery of 5.5 x 10 8 to 5.5 x 10 9 PFU/mL within rats. Clearly, there is interplay between the growth factor delivered and endogenous processes at the defect site, which ultimately control the response observed. It is therefore valuable to successful tissue engineering strategies, to investigate and compare these interactions.
Combination administration of PDGF
A number of studies have investigated combination treatment with PDGF and several other growth factors including bFGF (Meraw et al., 2000) , BMP-2 (Martino et al., 2011 ), BMP-7 (Zhang et al., 2009b , IGF-1 (Nociti Junior et al., 2000) , osteogenin (Marden et al., 1993) , TGF-β1 and VEGF (El Backly et al., 2013) . Bone formation was reported to increase between 1.4 and 2.3 fold (Zhang et al., 2009b) within large animals (dog (Zhang et al., 2009b) ) following PDGF dosages around 5 µg/mL for direct administration (Nociti Junior et al., 2000) , or 2 x 10 10 /mL viral particles for indirect administration (Zhang et al., 2009b) . Combination treatments within small animal (mouse (El Backly et al., 2013) , rabbit and rat (Park et al., 2013) ) studies reported increased bone formation between 2.5 and 10 fold following PDGF dosages ranging between 0.05 (Martino et al., 2011) and 200 µg (Marden et al., 1993) .
Tissue engineered bone and clinical translation PTH PTH is an 84 amino acid polypeptide secreted by chief cells of the parathyroid gland and is an essential regulator of both calcium and phosphate metabolism which has important ramifications for bone. Regarding mineral homeostasis, PTH acts to increase serum calcium through gastrointestinal absorption, renal reabsorption and liberation from bone reserves (Alkhiary et al., 2005; Podbesek et al., 1983) . Continuous PTH treatment results in bone resorption, functioning indirectly through osteoblasts rather than directly via osteoclasts. However, intermittent PTH treatment has been shown to result in osteoblast stimulation and increased bone formation (Hock and Gera, 1992) .
Direct administration of PTH
Many truncated forms of PTH have been directly administered in vivo most often by subcutaneous injection within large (dog (Daugaard et al., 2012) , monkey (Vahle et al., 2008) and sheep (Arrighi et al., 2009) ) and small animals (mouse , rabbit (Lehman et al., 2010) and rat (Qiu et al., 2013) ) at variable dosages from 0.75 to 7.5 µg/kg/day (Manabe et al., 2007) (20 to 1,000 µg/mL (Arrighi et al., 2009; Jung et al., 2007a) ), and 0.05 to 800 µg/kg/day (Mohan et al., 2000; RihaniBisharat et al., 1998 ) (20 to 100 µg/mL (Jung et al., 2007b) ), respectively (Supplementary Table 5 ). Treatment resulted in enhanced bone formation between 1.1 and 3.4 fold (Arrighi et al., 2009; Vahle et al., 2008) within large animals, and between 1.1 and 13.1 fold (Komatsu et al., 2009; Li et al., 2001) in small animals. Respective bone mechanical strength was also increased ranging from 1.4 to 2 fold (Daugaard et al., 2011; Vahle et al., 2008) for large animals and 1.1 to 3.8 fold Sloan et al., 2010) for small animals. Thus teriparatide (PTH 1-34), the truncated PTH molecule, is a successful osteoporosis molecule with clear anabolic bone formation activity. In brief, PTH administration leads to increased bone formation and mechanical strength over time, possibly through a reduction in osteoclast number (Manabe et al., 2007) . Indeed, Nozaka et al. (2008) reported a 5.3-fold reduction in osteoclast number. However, other studies by O'Loughlin et al. (2009) and reported contrasting results with a 2.5-to 4-fold increase in osteoclast number. Markers of bone formation such as osteocalcin and alkaline phosphatase were also shown to be increased between 1.2 and 3.1 fold (Komrakova et al., 2011; Qiu et al., 2013) , indicating upregulation of osteoblast activity. PTH-enhanced osteoblast activity has been shown to reduce periodontal disease-induced bone loss by as much as 2.3 fold (Marques et al., 2005) . Conversely, continuous PTH infusion, investigated by , demonstrated a significant drop in bone formation markers (3 to 7.5-fold drop in osteoprotegrin which binds RANKL blocking RANK-induced osteoclastogenesis) and increase in RANKL expression (5.5 to 27 fold) leading to a 3 fold increase in osteoclast number. Consequently, the adopted administration regimen has significant implications for bone formation. Vahle et al. (2004; showed treatment withdrawal reversed bone enhancement after 3 years in sheep and 24 months in rat. Caution should therefore be taken when striking a balance between treatment period and, importantly, dosage, as Vahle et al. (2004) Li et al. (2001) reported a significant difference in the potency of two differently sourced PTH peptides, where bovine PTH was 4 to 6 fold more potent than rat PTH. As previously mentioned, some studies have investigated cartilage formation as a precursor to bone tissue generation. Following PTH treatment chondrogenesis/cartilage formation was increased 3 to 9.9 fold (Kakar et al., 2007; O'Loughlin et al., 2009) leading to enhanced trabeculated callus formation . Bone architecture and structure are important quality indicators, yet many studies report only simple measurements of bone quantity. et al., 2003b) , IL-6 (Rozen et al., 2007) and PTHrP (Xue et al., 2005) , and bisphosphonates including alendronate (Campbell et al., 2011) , ibandronate , pamidronate (Aspenberg et al., 2008) , tiludronate (Delmas et al., 1995) and zoledronic acid . Some studies have delivered PTH with cells, including periodontal ligament cells (Wolf et al., 2012) , BMSCs (Pettway et al., 2005) and MSCs (Yu et al., 2012b) . Together, these studies have demonstrated increased bone formation between 1.3 (Morgan et al., 2008) and 4.1 fold (Kempen et al., 2010) in small animals following dosages from 10 to 90 μg/ kg/day. One large animal study demonstrated between 2 and 4 fold increased bone formation, following dosages of 0.015 µmol/kg (Delmas et al., 1995 et al., 2002) . In adults, PTHrP interferes with osteocytemediated sclerostin inhibition of bone formation (Robling et al., 2008) , and binds receptors of the osteoblast lineage inducing enhanced bone formation (Karaplis, 2001) .
Combination administration of PTH PTH has been used in combination treatment of bone defects with growth factors including BMP-2 (Kempen et al., 2010), BMP-7 (Morgan et al., 2008), FGF-2 (Lane
Direct administration of PTHrP
PTHrP analogues and truncated peptides have been utilised directly in small animal models, including mouse , rabbit (Trejo et al., 2010) , and rat (Supplementary Table 6 ). Bostrom et al. (2000) injected the PTHrP analogue RS-66271 within a rabbit ulna segmental defect (1 mm), whilst Trejo. et al. (2010) implanted the C-terminal PTHrP (107-111) epitope within a rabbit femur epiphyseal defect (5 mm). These two studies demonstrated a 2 to 10 fold increase in bone volume (Table 5 ). Analogues and truncated peptides have also been assessed in disease models. The C-terminal PTHrP (107-139) peptide and N-terminal PTHrP (1-36) peptide were examined within diabetic mice and found to reverse diabetic-induced bone loss when administered at 100 µg/kg every other day. Interestingly, the N-terminal PTHrP (1-36) peptide (40 µg/kg/day) and PTHrP analogue RS-66271 (80 µg/kg/ day) were investigated in ovariectomised rats (osteopaenia model) and found to reverse bone loss and enhance new bone formation exhibiting increased (3 fold) biomechanical strength Vickery et al., 1996) . Porto-Nunez et al. (2010) and de Castro et al. (2011) both used the N-terminal PTHrP (1-36) and the C-terminal PTHrP (107-139) peptides in combination in the ovariectomised and diabetic mice, respectively. Following injections at 80 and 100 µg/kg, bone loss was reversed and bone volume increased 1.5 fold. Although, different dosage regimes were implemented between these two studies, both observed an increase in BMD; 1.1 and 2.2 fold. Evidently, PTHrP plays an important role in bone formation and use of active analogues and peptides will not only augment bone healing, but can also reverse bone loss due to disease.
Combination administration of PTHrP
TGF-β3
A central component of the healing cascade in any bone defect is the formation of cartilage tissue, a precursor to immature bone, which subsequently becomes mineralised (Dimitriou et al., 2005) . TGF-β3 is a potent chondrogenic growth factor enhancing hyaline cartilage formation in vivo (Ripamonti et al., 2009a; Tang et al., 2009) . Ripamonti et al. (2009b; and Teare et al. (2008) investigated the direct delivery of TGF-β3 (5 to 125 µg) within adult Chacma baboons and demonstrated a 1.75-to 3-fold increase in bone formation (Supplementary Table  7 ). Direct TGF-β3 delivery (3 ng to 2.75 µg) within small animal models, including mouse (Kovacevic et al., 2011) and rat (Opperman et al., 2002) , only showed a 1.05 fold increase in bone volume. However, cartilage formation showed a more robust augmentation of 1.23 fold ( Table  5) . Low level bone formation was also observed by Rizk and Rabie (2013) , following investigation of TGF-β3 transduced cells within a mouse ectopic subcutaneous implant model; considerable cartilage constructs were generated without significant bone formation. Release of the chondrogenic factor TGF-β3 in vivo would be anticipated to induce cartilage formation. An appropriate osteogenic signal would then be required to drive mineralisation of this induced cartilage. Indeed, addition of OP-1 (Ripamonti et al., 2010) or MSCs (Mrugala et al., 2008) within large animal models has been shown to increase bone formation 5.3 fold; a vast improvement over TGF-β3 alone.
Direct administration of TGF-β3
Combination administration of TGF-β3
Small animal studies have investigated TGF-β3 delivery in combination with BMP-2 (Oest et al., 2007) , chondrocytes (Park et al., 2010b) , MSCs (Park et al., 2010a) , Sox9 (Park et al., 2012) , and TGF-β1 (Kim et al., 2010a) . Between 10 and 100 ng/mL TGF-β3 was used within these studies and TGF-β3 in combination with BMP-2 induced 12.8 to 13 fold more bone (Oest et al., 2007; Simmons et al., 2004) where combination with chondrocytes induced 1.6 to 22 fold increased collagen (Na et al., 2006; Park et al., 2009) . These studies confirm the combination of chondrogenic and osteogenic factors in a defined spatiotemporal pattern can lead to more enhanced bone tissue formation than application of TGF-β3 alone.
VEGF
VEGF constitutes a sub-family comprised of 5 members (VEGF-A to VEGF-D, and placental growth factor). VEGF-A is the most important of these members with a significant role in both vasculogenesis (de novo vasculature formation) and angiogenesis (vessel formation sprouting from existing vasculature) (Byrne et al., 2005) . Hypoxia and necrosis are major concerns at sites of bone damage and contribute to healing failure. Formation of healthy vasculature through the use of VEGF-A to supply oxygen and nutrients at these sites is of paramount importance to efficient bone defect regeneration (Geiger et al., 2007) .
Direct administration of VEGF
Currently only a limited number of studies have utilised VEGF for in vivo bone defect regeneration (Supplementary Table 8 ). Kanczler et al. (2008) implanted 1.7 μg rhVEGF 165 on poly(lactic acid) (PLA) scaffold within a mouse femur 5 mm segmental defect. After 4 weeks, augmentation of blood vessel formation was observed alongside a 1.65-fold increase in bone volume (Table 5 ). The same study implanted human BMSCs in combination with rhVEGF 165 but observed no further enhancement. A study by Wernike et al. (2010) observed enhanced vascularisation but negligible impact on bone regeneration within a mouse calvarial 4 mm drill defect.
Indirect administration of VEGF
A number of studies have investigated indirect delivery of VEGF 165 through implantation of plasmid DNA within a mouse femur 8 mm defect (Keeney et al., 2010) , or transfected cells within rabbit long bone 10 mm and 15 mm segmental defects (Geiger et al., 2007; Li et al., 2009b ).
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Together these studies demonstrated 1.6-to 2-fold increase in bone formation with augmented vascularisation.
Combination administration of VEGF
A number of studies have explored the application of angiogenic VEGF (0.2 to 20 μg) and osteogenic BMP-2 (0.5 to 120 μg) in combination within large animals, including dog (Geuze et al., 2012) and pig (Ramazanoglu et al., 2011) , and small animals, including mouse (Behr et al., 2012; Samee et al., 2008) , rabbit (Hernandez et al., 2012) , and rat (Kempen et al., 2009) . Roldan et al. (2010) and Zhang et al. (2010a) combined VEGF with BMP-7 and observed neovascularisation in the absence of any significant increase in bone regeneration. Li et al. (2009a) investigated the use of VEGF with BMP-4 and observed impaired ectopic bone formation using a high VEGF ratio. Interestingly, when VEGF release was slow and sustained, impairment was no longer observed. Recruitment of blood vessels into the defect site, instructed by VEGF, typically complicates bone formation due to the increased localised bone remodelling and callus formation by osteoblasts. Zhang et al. (2011a) found that VEGF delivery using a hydrogel resulted in faster degradation, which ultimately has repercussions for controlled dual growth factor release profiles. It is thus self-evident that spatiotemporal control over select growth factor release for induction of angiogenesis, chondrogenesis, and osteogenesis is central for successful bone tissue repair.
Wnt Proteins
A diverse family of signalling glycoproteins (19 members; Wnt1 to Wnt16), Wnt proteins are involved in a myriad of cellular processes, including cell proliferation, migration and differentiation (De Boer et al., 2004) . Zhou et al. (2009) injected 100 ng Wnt3A into a mouse model of delayed skeletal development and observed both increased parietal bone volume and a 1.4 fold reduction in suture area (Supplementary Table 9 ). Only one other study, at the time of writing this review, had investigated Wnt3A utilisation, using liposomal vesicle injection for direct delivery of Wnt3A to 1 mm tibial mouse fracture model and demonstrated accelerate mineralisation and osteoid deposition' (Minear et al., 2010) .
Direct administration of Wnt proteins
Indirect administration of Wnt proteins
Given the cost of Wnt proteins, focus has centred on indirect delivery using transduced and transfected cells (Table 5) . Nalesso et al. (2011) and Qiang et al. (2008) both injected Wnt3A-transfected cells within severe combined immuno deficient (SCID) mice and observed 1.5 fold increased cartilage formation and 1.12 fold increased BMD. Liu et al. (2009) injected Wnt1 transduced cells within SCID mice and observed a dose dependent enhancement of bone formation (1.25 fold). Implantation of Wnt4 transduced MSCs in SCID mice with a 5 mm calvarial defect resulted in extensive integrated enhanced mineralised bone tissue (Chang et al., 2007) . The same study implanted Wnt1 transduced cells within an alveolar defect in SCID rats and observed a 3-to 5-fold increase in bone formation. 1.75 fold increased bone formation was also observed by Bennett et al. (2005; within transgenic mice following Wnt10B plasmid injection into mouse embryos. These different studies indicate that Wnt proteins can augment in vivo bone formation, although success in bone tissue engineering will be dependent on Wnt protein selection. Injection of Wnt6 transfected cells within the chick limb bud inhibited chondrogenesis and promoted myogenesis (Geetha-Loganathan et al., 2010) . Wnt5A plasmid injection within mouse embryos generated transgenic mice exhibiting a variety of developmental defects, including reduced endochondral and intramembranous bone formation (van Amerongen et al., 2012) , although control of spatiotemporal expression exhibited increased calvarial ossification. In summary, select exogenous factors can be successfully applied as part of a tissue-engineering regimen for in vivo bone regeneration. It is the opinion of the authors that BMP-2 provides the greatest bone regeneration in vivo, and that careful spatiotemporal release with additional factors may provide synergistic or additional signalling leading to further augmentation. Supporting literature discussed here details a maximum 50-fold increase in bone formation following BMP-2 administration ( Table  5) . BMP-7 may provide a suitable alternative to BMP-2 with similar osteogenic potency. However, many studies failed to quantify enhanced tissue formation or failed to record any changes therein and therefore recorded fold increases may indeed be higher. Nevertheless, these animal studies have informed clinical translation resulting in BMP-2, BMP-7/OP-1, PDGF, PTH and PTHrP transition from animals to humans. The current prohibitive protein production costs or minimal supporting in vivo literature may explain the lack of FGF, TGF-β3, VEGF and Wnt protein clinical translation to date.
Human Trials
In contrast to animal models, human patients display unpredictable idiopathic variations in their ability to form bone, inter and intra-family genetic variations, and systemic multifactorial inconsistencies derived from age, sex, weight, diet, disease, health status, lifestyle, medication, drug abuse/addiction, and numerous environmental factors (Sandhu et al., 1995) . Consequently, large subject numbers are required in any clinical trial before examination can yield comparative data of value (Khan and Lane, 2004) . That said, tissue engineering-based approaches to bone regeneration in humans have already been successfully translated.
BMP-2
Approval for the use of rhBMP-2 in humans was granted by the European Medicines Agency in 2002, and by the U.S. Food and Drug Administration (FDA) in 2004 (McKay et al., 2007 , following a pivotal study by the BESTT (BMP-2 evaluation in surgery for tibial trauma) study group (Govender et al., 2002) . The study reported both a reduced need for secondary intervention, and enhanced fracture healing following treatment with rhBMP-2 on absorbable D Gothard et al. Tissue engineered bone and clinical translation collagen sponge (ACS). BMP-2 has subsequently become the subject of intense examination in vivo (Supplementary Table 1 ). Clinical studies have included facial reconstruction (cleft and mandible defects) (Cicciu et al., 2012; Dickinson et al., 2008; Herford and Boyne, 2008) , maxillary sinus floor augmentation ), long bone non-unions (Tressler et al., 2011 , tibial fractures Swiontkowski et al., 2006) , and lumbar fusions (Mladenov et al., 2010; . Facial reconstruction and bone augmentation studies all delivered rhBMP-2 on ACS at a concentration of 0.75 to 1.5 mg/mL. Boyne et al. (2005) demonstrated increased bone formation suitable for dental implants. Fiorellini et al. (2005) and performed similar dental studies revealing 2-fold increase in bone formation for dental implants and functional longevity, respectively. Dickinson et al. (2008) also demonstrated the efficacy of rhBMP-2/ACS for bone regeneration in vivo through improved healing and reduced morbidity in cleft defects. Treated patients exhibited 95 % closure compared to 63 % in non-treated patients. New bone formation and closure of non-union fractures was observed by Tressler et al. (2011) and Johnson et al. (1988b) . Additional advantages of utilising rhBMP-2 on ACS over iliac crest autograft included 1.35 fold reduced operative time and 1.4 fold reduced intraoperative blood loss, both of which aided effective surgery (Tressler et al., 2011) . 92.3 % to 98 % of treated patients Haid et al., 2004) compared with 70 % to 89 % of control patients Dimar et al., 2009 ) exhibited successful fusions of lumbar vertebrae, demonstrating enhancement of rhBMP-2-induced bone formation (Supplementary Table 1 ). Other rhBMP-2 studies reported reduced back and leg pain (Burkus et al., 2003a) and reduced arm and neck pain (Baskin et al., 2003) . The major carrier utilised for rhBMP-2 was ACS, however alternative carriers were utilised including autograft and allograft bone (Buttermann, 2008; , gelatin (Johnson et al., 1988a) , hydroxyapatite-tricalcium phosphate particles (Dawson et al., 2009), polyetheretherketone (Klimo and Peelle, 2009) , and poly(lactic co-glycolic acid) (Johnson et al., 1988b; Katayama et al., 2009) . However, in the last few years a number of studies have questioned adverse-free outcomes of rhBMP-2 for spinal fusion. Off label use of rhBMP-2, reported within several studies, has shown significant rhBMP-2-related side effects including urogenital and renal complications, wound complications, increased inflammation and increased cancer risk (Carreon et al., 2008; Mesfin et al., 2013; Moshel et al., 2008) . Fu et al. (2013) stated, "early journal publications misrepresented the effectiveness and harms through selective reporting, duplicate publication, and underreporting", in their assessment of rhBMP-2 use in spine fusion surgery (Fu et al., 2013) . Thus, standardisation of analysis methodology and readout parameters would benefit comparison between studies regarding BMP-2 safety and efficacy.
BMP-7/OP-1
Early studies utilising BMP-7 in humans were first reported between 1999 and 2001 (Friedlaender et al., 2001; Geesink et al., 1999; Laursen et al., 1999; van den Bergh et al., 2000) . These studies investigated BMP-7 delivery on ACS to long bone osteotomy and non-union, lumbar interbody fusion and maxillary sinus augmentation (Supplementary Table 2 ). Van den Bergh et al. (2000) and Groeneveld et al. (1999) reported 1.2 to 9.7 fold increased osteoid formation following treatment with 2.5 mg BMP-7 for maxillary sinus augmentation. Less successful outcomes were reported by Laursen et al. (1999) and Jeppsson et al. (1999) regarding lumbar fusions, where enhanced bone resorption was observed and only 1 of 4 patients exhibited successful bone bridging. Conversely, Geesink et al. (1999) demonstrated new bone formation within tibial osteotomies as early as 6 weeks following treatment with 2.5 mg BMP-7 in all but one patient. Friedlaender et al. (2001) demonstrated safe application of BMP-7 in vivo with non-union healing comparable to autograft controls. Together, these studies pioneered BMP-7 use in vivo and led to FDA approval for use in long bone non-unions in 2001 and posterolateral lumbar fusions in 2004 (Ong et al., 2010) . Regarding lumbar fusion surgery, BMP-7 was delivered at 3.5 mg per vertebral side (7 mg in total). Vaccaro et al. (2003; 2004; reported improved Oswestry scores measuring low back pain, radiographic fusion in 50 % to 55 % of patients, and bone bridging in 70 % to 91 % of patients. BMP-7 was repeatedly shown to increase bone formation similar to autograft (Johnsson et al., 2002; Kanayama et al., 2006; . However, over-zealous application of BMP-7 can have side effects, as Kim et al. (2010b) demonstrated significant ectopic bone formation along the surgical track following delivery of 17.5 mg. It is important to note that dosage is relative to defect site and that where high dose in one anatomic location may be excessive, in another location within a different size defect the same dose may be more appropriate. Indeed, 17.5 mg appeared excessive in lumbar fusion, but Hernandez-Alfaro et al. (2012) demonstrated safe administration of 2 g BMP-7 within a 60 mm mandibular defect and reported stable osseointegration of titanium mesh implant after 1 year. Numerous pseudarthrosis and non-union fracture studies standardised BMP-7 dosage to 3.5 mg. Complete defect healing was observed in patients treated for pseudarthrosis, where treated bones were reportedly pain free and load bearing (Anticevic et al., 2006; Fabeck et al., 2006) . However, Lee et al. (2006) did not observe new bone formation in any of the 5 patients that received treatment. A study by Ekrol et al. (2008) also demonstrated a lack of BMP-7 induced bone healing within radial osteotomies reporting decreased healing rates and reduced stability compared to autograft. Non-union fracture studies reported better results following administration of 3.5 mg BMP-7. 75 % (Friedlaender et al., 2001) to 100 % ) of treated patients exhibited healed defects within 3 (Kanakaris et al., 2008) to 16 months . This compared with only 68.3 % (Calori et al., 2008) to 85 % (Friedlaender et al., 2001) of patients who received autograft. These studies also reported decreased healing time (1.5 fold), hospital stay (3.4 fold) and treatment cost (1.9 fold) (Dahabreh et al., 2007; Ristiniemi et al., 2007) . Taken together, current literature supports the application of BMP-7 within tissue engineering strategies for localised D Gothard et al. Tissue engineered bone and clinical translation bone defect repair and regeneration. However, dosage should be carefully considered with respect to the defect site to reduce unwanted side effects.
PDGF
Only one study, at the time of writing, was found to utilise PDGF for in vivo bone regeneration in humans. Nevins et al. (2003) administered between 0.5 and 5 mg/mL PDGF-BB to patients with advanced periodontitis and interproximal intrabony and/or molar class II furcation defects (Supplementary Table 4 ). As with all human studies, investigation of new bone is limited and analysis of specific bone parameters is restricted to non-invasive techniques. The study assessed defect regeneration through vertical probing depth and found a 1.12 fold reduction following PDGF treatment compared to xenograft bone in collagen. Clearly, PDGF treatment provides a functional alternative to xenograft for effective defect regeneration.
PTH
PTH has been administered in humans for many years investigating its efficacy for bone formation within healthy adults (Horwitz et al., 2011) , adults with low BMD (Ryder et al., 2010) , postmenopausal women (Schafer et al., 2013) , mandibular defects (Kwon et al., 2012) and vertebral fractures (Supplementary Table  5 ). Continuous delivery has been shown to reduce bone formation markers and increase bone resorption. Horwitz et al. (2011) indeed demonstrated extensive bone resorption with high dose PTH (4 pmol/kg/h) delivered by continuous infusion pump, resulting in hypercalcemia. Intermittent delivery increased bone turnover within low BMD patients who exhibited 2.1 fold increased bone formation, and 2.7 fold increased bone resorption (Ryder et al., 2010) . Nakamura et al. (2012) also demonstrated increased BMD (2.3 to 6 fold) within vertebral fracture patients following intermittent administration (56.5 μg/week). Standard delivery of PTH at 20 μg/d to patients with mandibular defects resulted in 5.4 to 5.7 fold increased bone marker expression (Kwon et al., 2012 ), and 1.5 (Kuchler et al., 2011 ) to 11.6 fold (Bashutski et al., 2010 increased bone formation with augmented implant integration (1.2 to 4.7 fold). Most studies reviewed investigated PTH administration within postmenopausal women at dosages ranging between 20 and 100 μg/d. These studies reported reduced healing time (1.3 (Aspenberg et al., 2010 ) to 1.6 fold (Peichl et al., 2011) ) and fracture incidence (2.8 to 7 fold) (Neer et al., 2001) , whilst BMD and mechanical strength were reportedly increased 1.02 to 1.05 fold (Keaveny et al., 2012) , and 4.2 to 7.7 fold (Keaveny et al., 2008) , respectively. Clearly, PTH can augment bone defect repair and increase innate BMD.
PTHrP
PTHrP has been used clinically via subcutaneous or intravenous injection. Horwitz et al. (2011; published data detailing systemic delivery of N-terminal PTHrP (1-36) peptide within healthy adults at dosages between 2 and 28 pmol/kg/h led to profound suppression of bone formation (Supplementary Table 6 ). Another study revealed that 1.3-to 1.4-fold suppression in bone formation could be reversed following PTHrP analogue cessation. Consequently, continuous infusion can enhance bone resorption and decrease bone formation, whilst intermittent infusion can lead to a net increase in bone formation. Fraher et al. (1992) demonstrated increased serum calcium and urinary phosphate when healthy individuals were injected with N-terminal PTHrP (1-34) peptide at 8 or 80 pmol/kg/h. Thus, PTHrP translation from animal to human studies has, to date, not yielded similar responses, indeed the use of PTHrP analogues has had the opposite effect with increased bone resorption observed in the clinic. However, a study by Plotkin et al. (1998) using the N-terminal PTHrP (1-36) peptide delivered by subcutaneous injection within post-menopausal oestrogen deficient women observed activation of bone formation and a 1.3-to 1.45-fold reduction in bone resorption. The function of these analogues may be modified by the hosts hormonal status; pre or post-menopause. Minimal literature on the in vivo use of PTHrP analogues highlights the need for further investigation before definitive conclusions can be drawn.
Future directions
It is clear the use of select growth factors in vivo can augment bone formation and potentially repair defects.
Utilisation of animal models has proven informative for clinical translation of bone tissue engineering strategies. However, complications associated with spatiotemporal release of growth factors regarding longevity, bioactivity and carrier release kinetics have impeded progress. Parallel, synergistic and consecutive delivery of multiple growth factors appears key to successful bone regeneration. The authors envisage coordinated spatiotemporal release of select growth factors recapitulating in vivo signalling cascades leading to bone tissue formation. The importance of understanding the developmental processes underpinning bone tissue formation, and their importance in contextualising signalling cascades and the growth factors involved in regenerative medicine is gaining prominence, as understanding these processes is vital to informed clinical bone therapies (Smith et al., 2013; Turner et al., 2013) . The data presented here demonstrate the complex and convoluted interplay between administered growth factors with variable success for bone tissue formation dependent on species, dosage and combination. Thus, before robust bone tissue engineering can be achieved (and more importantly interpreted), it will be important to understand the functional interplay between growth factors and how this leads to bone formation under different conditions. For example, the chick model provides an ideal system for investigating bone development biology (Smith et al., 2013) . Organotypic culture of embryonic chick femora ex vivo enables investigation and elucidation of processes involved in skeletal development and bone repair Smith et al., 2014a; Smith et al., 2014b; . Models such as the chick may indeed fulfil the requirement for a simple, relatively here. However, a lack of bone tissue quantification and adequate controls limits correlation between growth factor efficacy in animals and that in humans. This further highlights the need for standardised investigation with specified measurable parameters in vivo. Connecting observations in animal models to those in humans will, ultimately, further our understanding of growth factor induced bone formation. Controlled orchestration of clinically relevant and functional in vivo bone formation may finally deliver on the long heralded promise of bone regeneration for an increasingly aged population. 
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